VB10.16
Phase 2Biologic
VB10.16 is one of 84 biologic programs targeting Cervical Cancer. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
380 competitors in Cervical Cancer
#DrugCompanyPhaseTrials
1Trodelvy
GileadPhase 3
Emend IV
Merck & Co.Phase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Platinum Based Chemotherapy
RochePhase 3
Gemzar
Eli LillyPhase 3
Epoetin Beta
RochePhase 3
Zimberelimab
Arcus BiosciencesPhase 3
Gemcitabine and Cisplatin
FForma Therapeutics, Inc.
Phase 3
SHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cervical Cancer2 trials
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VB10.16. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- NNykode Therapeutics ASA